Clarkston Capital Partners LLC Sells 9,450 Shares of IQVIA Holdings Inc. $IQV

Posted by Brian Himes on Jun 13th, 2026

Clarkston Capital Partners LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 252,525 shares of the medical research company’s stock after selling 9,450 shares during the quarter. IQVIA makes up approximately 1.3% of Clarkston Capital Partners LLC’s portfolio, making the stock its 25th largest holding. Clarkston Capital Partners LLC’s holdings in IQVIA were worth $56,922,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Eagle Rock Investment Company LLC raised its position in shares of IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after purchasing an additional 11,657 shares during the period. EDENTREE ASSET MANAGEMENT Ltd bought a new position in shares of IQVIA in the third quarter valued at approximately $7,368,000. AMG National Trust Bank bought a new position in shares of IQVIA in the third quarter valued at approximately $3,713,000. Citigroup Inc. raised its position in shares of IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock valued at $173,830,000 after purchasing an additional 475,557 shares during the period. Finally, Dana Investment Advisors Inc. raised its position in shares of IQVIA by 18.4% in the third quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company’s stock valued at $30,401,000 after purchasing an additional 24,854 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.0%

IQV opened at $181.10 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $153.01 and a fifty-two week high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm’s fifty day moving average price is $173.56 and its two-hundred day moving average price is $193.68. The company has a market capitalization of $30.23 billion, a P/E ratio of 22.44, a P/E/G ratio of 1.55 and a beta of 1.21.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the company earned $2.70 earnings per share. The business’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its Board of Directors has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research report on Friday, March 6th. HSBC set a $210.00 target price on shares of IQVIA in a research report on Wednesday, June 3rd. Mizuho set a $215.00 target price on shares of IQVIA in a research report on Monday, February 23rd. Finally, Morgan Stanley set a $225.00 target price on shares of IQVIA in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Buy” and a consensus target price of $224.13.

View Our Latest Stock Report on IQVIA

IQVIA Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Clarkston Capital Partners LLC Sells 9,450 Shares of IQVIA Holdings Inc. $IQV

IQVIA Stock Up 0.0%

Analyst Upgrades and Downgrades

IQVIA Profile

Further Reading

You might be interested in: